← Leaderboards
Manesh R Patel
Cohere-Med, Inc.
$7,406,641
Attributed
$14,990,287
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,990,287 · 8
By mechanism
UH3$5,557,295 · 2
UG3$3,387,238 · 2
R01$2,301,658 · 1
R42$2,114,202 · 1
R44$1,382,148 · 1
R43$247,746 · 1
Top collaborators
- Panagiotis Kougias5 shared
- Firas Fuad Mussa5 shared
- Ricardo Henao Giraldo4 shared
- Santosh Venkatesha4 shared
- Sreekanth Vemulapalli3 shared
- Jennifer Rymer2 shared
Others in their field
Other Emerging Leaders on “Cost”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Scott Topper · Broad Institute, Inc.$77,958,806
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Mark Marino · Venturewell$48,913,644
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,367,817
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
Research focus
CostMorbidity - Disease RateEventNational Heart, Lung, And Blood InstituteMortalityDesignEnrollmentCessation Of LifeGuidelinesResearch PersonnelBlood VesselsFundingPrevalenceCaringHospital MortalityHypertensionStandard Of CarePharmaceutical PreparationsOperative Surgical ProceduresMedicineIncidenceImageSiteSubgroup
Grant awards (17)
1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)$1,864,327
UH3 · FY2025 · HL · contact PI
1/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)$1,841,946
UH3 · FY2025 · HL · contact PI
1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)$5,355
UH3 · FY2025 · HL · contact PI
1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)$5,355
UH3 · FY2025 · HL · contact PI
1/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)$1,858,859
UG3 · FY2024 · HL · contact PI
1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)$1,840,312
UH3 · FY2024 · HL · contact PI
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning$925,681
R42 · FY2024 · GM · contact PI
1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)$1,528,379
UG3 · FY2023 · HL · contact PI
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning$912,755
R42 · FY2023 · GM · contact PI
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning$275,766
R42 · FY2022 · GM · contact PI
BEST-VIVA Registry (vCLI)$745,998
R01 · FY2021 · HL · contact PI
BEST-VIVA Registry (vCLI)$770,362
R01 · FY2020 · HL · contact PI
Enhanced x-ray angiography analysis and interpretation using deep learning$702,450
R44 · FY2020 · HL
BEST-VIVA Registry (vCLI)$785,298
R01 · FY2019 · HL · contact PI
Enhanced x-ray angiography analysis and interpretation using deep learning$679,698
R44 · FY2019 · HL
Enhanced x-ray angiography analysis and interpretation using deep learning$217,746
R43 · FY2018 · HL
Enhanced x-ray angiography analysis and interpretation using deep learning$30,000
R43 · FY2018 · HL